138 related articles for article (PubMed ID: 34383097)
1. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
Rosenberg D; Avni T; Tsvetov G; Gafter-Gvili A; Diker-Cohen T
Osteoporos Int; 2021 Oct; 32(10):2131. PubMed ID: 34383097
[No Abstract] [Full Text] [Related]
2. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
Rosenberg D; Avni T; Tsvetov G; Gafter-Gvili A; Diker-Cohen T
Osteoporos Int; 2021 Mar; 32(3):413-424. PubMed ID: 33145606
[TBL] [Abstract][Full Text] [Related]
3. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.
Menshawy A; Mattar O; Abdulkarim A; Kasem S; Nasreldin N; Menshawy E; Mohammed S; Abdel-Maboud M; Gadelkarim M; El Ashal GG; Elgebaly AS
Support Care Cancer; 2018 Apr; 26(4):1029-1038. PubMed ID: 29387997
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials.
Seeto AH; Abrahamsen B; Ebeling PR; Rodríguez AJ
J Bone Miner Res; 2021 Jan; 36(1):24-40. PubMed ID: 32780899
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.
Sun L; Yu S
Am J Clin Oncol; 2013 Aug; 36(4):399-403. PubMed ID: 22772430
[TBL] [Abstract][Full Text] [Related]
6. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
[TBL] [Abstract][Full Text] [Related]
7. Denosumab: a case of MRONJ with resolution.
Lyttle CV; Patterson H
Br Dent J; 2016 Jun; 220(12):623-5. PubMed ID: 27338901
[TBL] [Abstract][Full Text] [Related]
8. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
[TBL] [Abstract][Full Text] [Related]
9. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
[TBL] [Abstract][Full Text] [Related]
10. Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis.
Diker-Cohen T; Rosenberg D; Avni T; Shepshelovich D; Tsvetov G; Gafter-Gvili A
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31899506
[TBL] [Abstract][Full Text] [Related]
11. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
[TBL] [Abstract][Full Text] [Related]
12. Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
Chen F; Pu F
Oncol Res Treat; 2016; 39(7-8):453-9. PubMed ID: 27487236
[TBL] [Abstract][Full Text] [Related]
13. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
Boquete-Castro A; Gómez-Moreno G; Calvo-Guirado JL; Aguilar-Salvatierra A; Delgado-Ruiz RA
Clin Oral Implants Res; 2016 Mar; 27(3):367-75. PubMed ID: 25639776
[TBL] [Abstract][Full Text] [Related]
14. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
[TBL] [Abstract][Full Text] [Related]
15. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of the Jaw.
Hamdy RC
J Clin Densitom; 2017; 20(1):1-2. PubMed ID: 28259260
[No Abstract] [Full Text] [Related]
17. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
18. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
Awan AA; Hutton B; Hilton J; Mazzarello S; Van Poznak C; Vandermeer L; Bota B; Stober C; Sienkiewicz M; Fergusson D; Shorr R; Clemons M
Breast Cancer Res Treat; 2019 Aug; 176(3):507-517. PubMed ID: 31079283
[TBL] [Abstract][Full Text] [Related]
19. Maxillar osteonecrosis related to denosumab. Evaluation of nine cases.
Sánchez López JD; Cariati P; Pérez de Perceval Tara M
Med Clin (Barc); 2020 Aug; 155(4):180-181. PubMed ID: 31427154
[No Abstract] [Full Text] [Related]
20. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
